» Authors » K D Sievert

K D Sievert

Explore the profile of K D Sievert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 441
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Berges R, Sievert K, Gratzke C, Wetterauer U
Urologe A . 2013 Mar; 52(3):350-3. PMID: 23503793
The implantation of a tissue retractor (UroLift®, Neotract, Pleasanton, CA) allows for the first time as a non-ablative operative technique, moderate deobstruction without removal or destruction of prostate tissue. The...
12.
Herlemann A, Gratzke C, Andersson K, Sievert K
Urologe A . 2013 Feb; 52(2):204-11. PMID: 23417046
Phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil, tadalafil and vardenafil are first line treatment for erectile dysfunction (ED). These PDE5 inhibitors are known to increase cyclic guanosine monophosphate (cGMP) concentrations in...
13.
Mischinger J, Amend B, Reisenauer C, Bedke J, Naumann G, Germann M, et al.
Minerva Ginecol . 2013 Feb; 65(1):21-8. PMID: 23412017
Stress urinary incontinence (SUI) constitutes involuntary voiding as a consequence of rising intra-abdominal pressure caused by sphincter weakness. In recent years studies were published according to surgical SUI management evaluating...
14.
Amend B, Hennenlotter J, Kuehs U, Laible I, Anastasiadis A, Schilling D, et al.
World J Urol . 2011 Dec; 31(2):377-82. PMID: 22130650
Purpose: To study microscopic patterns of remaining peripheral nerves (PN) after nerve-sparing (NS) radical prostatectomy (RP) and possible consequences for nerve preparation. Methods: Specimens from 27 patients (7 = non-NSRP,...
15.
Amend B, Hennenlotter J, Scharpf M, Kruck S, Kuehs U, Senger E, et al.
World J Urol . 2011 Aug; 30(3):353-9. PMID: 21822918
Purpose: Renal oncocytomas are assigned as benign tumours, and their detailed molecular mechanism is poorly characterised. Activation of the PKB/Akt pathway is assumed to contribute to the pathogenesis and progression...
16.
Chartier-Kastler E, Castro-Diaz D, De Ridder D, Everaert K, Sievert K, Spinelli M, et al.
Prog Urol . 2009 Aug; 19(8):530-7. PMID: 19699450
The overactive bladder syndrome (OAB) negatively affects the daily life of many people worldwide and conservative treatments, such as antimuscarinics, not always bring relief and/or are associated with considerable side...
17.
Sievert K, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al.
World J Urol . 2009 Mar; 27(3):295-300. PMID: 19271220
Objective: Bladder cancer (BC) has the highest lifetime treatment costs per patient of all cancers. The high recurrence rate and ongoing invasive monitoring requirement are the key contributors to the...
18.
Schafer R, Dominici M, Muller I, Horwitz E, Asahara T, Bulte J, et al.
Cytotherapy . 2009 Jan; 11(2):245-55. PMID: 19152153
From 4 to 5 April 2008, international experts met for the second time in Tubingen, Germany, to present and discuss the latest proceedings in research on non-hematopoietic stem cells (NHSC)....
19.
Seibold J, Schilling D, Nagele U, Anastasiadis A, Sievert K, Stenzl A, et al.
J Pediatr Urol . 2008 Sep; 4(5):345-7. PMID: 18790417
Objective: Despite increasing acceptance of laparoscopy in pediatric urology, few published data are available on laparoscopic heminephroureterectomy in patients with duplex kidney anomalies. In the present study, we report our...
20.
Nagele U, Schilling D, Anastasiadis A, Walcher U, Sievert K, Merseburger A, et al.
Urologe A . 2008 Aug; 47(9):1066, 1068-73. PMID: 18709351
Minimally invasive percutaneous nephrolithopaxy (MIP) was developed to combine the excellent stone-free rates of the conventional percutaneous nephrolithopaxy (PCNL) technique with the low morbidity of the miniaturized PCNL (Mini-Perc) and,...